Evidence map›Paper›PMID 34680221›Full record

ArticleCancers2021

Periostin Exon-21 Antibody Neutralization of Triple-Negative Breast Cancer Cell-Derived Periostin Regulates Tumor-Associated Macrophage Polarization and Angiogenesis.

Tatsuya Fujikawa, Fumihiro Sanada, Yoshiaki Taniyama, Kana Shibata, Naruto Katsuragi, Nobutaka Koibuchi, Kaori Akazawa, Yuko Kanemoto, Hidehito Kuroyanagi, Kenzo Shimazu and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Macrophage-cancer cell crosstalk in breast cancer chemotherapy resistance.Medical oncology (Northwood, London, England) · 2025
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Mechanisms of RNA alternative splicing dysregulation in triple-negative breast cancer.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024
    Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Tatsuya FujikawaDepartment of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
Fumihiro SanadaDepartment of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.ORCID 0000-0002-3728-5607
Yoshiaki TaniyamaDepartment of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
Kana ShibataDepartment of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
Naruto KatsuragiDepartment of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
Nobutaka KoibuchiDepartment of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
Kaori AkazawaDepartment of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
Yuko KanemotoDepartment of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
Hidehito KuroyanagiDepartment of Biochemistry, Graduate School of Medicine, University of the Ryukyu, Okinawa 903-0213, Japan.ORCID 0000-0002-1563-1134
Kenzo ShimazuDepartment of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
Hiromi RakugiDepartment of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
Ryuichi MorishitaDepartment of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
The University of Osaka · JPUniversity of the Ryukyus · JP

Funding

Japan Society for the Promotion of Science JP20K07659, JP20H03181 and JP20K21385,Kondou Kinen Medical Foundation NAKurata Memorial Hitachi Science and Technology Foundation 1409Nanken-Kyoten, TMDU NA
6 · The paper itself

Abstract

Periostin (Pn) is involved in multiple processes of cancer progression. Previously, we reported that Pn expression is correlated with mesenchymal tumor markers and poor prognosis in triple-negative breast cancer (TNBC). In the TNBC xenograft model, chemotherapy increased expression of a Pn alternative splicing variant (ASV) with exon 21, and administration of the neutralizing antibody against Pn with exon 21 (Pn-21 Ab) overcame chemoresistance with a reduction in the mesenchymal cancer cell fraction. In the present study, the role of Pn ASV with exon 21 in TNBC progression has been addressed. We first established a stable cell line carrying a fluorescence-based splicing reporter. Pn-positive TNBC has higher expression of genes related to tumor-associated macrophage (TAM) recruitment and ECM-receptor interaction than Pn-negative cells. In a xenograft model, only Pn-positive cells initiated tumor formation, and the Pn-21 Ab suppressed tumor cell growth, accompanied by decreased M2 TAM polarization and the number of tumor vessels. These data suggest that cancer cell-derived Pn ASV educates TAMs and regulates angiogenesis, which in turn establishes a microenvironmental niche that is supportive of TNBC.

Indexed as

periostintriple-negative breast cancertumor-associated macrophage

Identifiers

PMID34680221
PMCPMC8533925
OpenAlexW3205155071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.